Evolving Strategies in Cardiac Amyloidosis
Heart Failure Clinics · 2026-04 · 22 (2) · 243-260
DOI: 10.1016/j.hfc.2025.11.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Clinics, 2026-04. Verfasst von Ashley F Stein-Merlob und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; UCLA Cardio-Oncology Program, Division o…. Hauptthemen laut MEDLINE: Cardiomyopathies, Amyloidosis. Die Arbeit nennt 106 Literaturangaben. Gefördert von: Clinical and Translational Science Institute, University of California, Los Angeles.
Abstract (Originalsprache)
Diagnosis and treatment of cardiac amyloidosis have rapidly evolved over the past decade by harnessing mechanisms of disease pathogenesis. Cardiac amyloidosis is caused by myocardial deposition of fibrils formed by misfolded proteins, namely transthyretin (ATTR) and immunoglobulin light chains (AL). Advances in noninvasive imaging have revolutionized diagnosis of ATTR cardiomyopathy (CM). Novel treatments for ATTR-CM utilize a range of therapeutic techniques, including protein stabilizers, interfering RNA, gene editing, and monoclonal antibodies. AL-CM, primarily driven by plasma cell dyscrasias, requires treatment with chemotherapy and consideration for autologous stem cell transplant. These incredible advances aim to improve patient outcomes in cardiac amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California, Los An…
- Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
- Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Department of Medicine, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, C…
Förderung
- Clinical and Translational Science Institute, University of California, Los Angeles
Zitieren
APA
Stein-Merlob, A. F., Swier, R., & Vucicevic, D. (2026). Evolving Strategies in Cardiac Amyloidosis. Heart Failure Clinics, 22(2), 243-260. https://doi.org/10.1016/j.hfc.2025.11.005
Vancouver
Stein-Merlob AF, Swier R, Vucicevic D. Evolving Strategies in Cardiac Amyloidosis. Heart Failure Clinics. 2026;22(2):243-260. doi:10.1016/j.hfc.2025.11.005
BibTeX
@article{SteinMerlob2026,
author = {Stein-Merlob, Ashley F and Swier, Rachel and Vucicevic, Darko},
title = {Evolving Strategies in Cardiac Amyloidosis},
journal = {Heart Failure Clinics},
year = {2026},
volume = {22},
number = {2},
pages = {243--260},
doi = {10.1016/j.hfc.2025.11.005}
}
EUVIMED